A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of esomeprazole 20 mg and 40 mg once daily oral administration with omeprazole 20 mg once daily oral administration in patients with reflux esophagitis.

Trial Profile

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of esomeprazole 20 mg and 40 mg once daily oral administration with omeprazole 20 mg once daily oral administration in patients with reflux esophagitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Esomeprazole (Primary) ; Omeprazole
  • Indications Reflux oesophagitis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Apr 2010 Actual patient number (602) added as reported by ClinicalTrials.gov.
    • 11 Mar 2009 Actual end date reported by ClinicalTrials.gov.
    • 11 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top